0000000000424832

AUTHOR

Marina Dolzhenko

showing 2 related works from this author

Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology …

2019

Aims The aim of this study was to determine whether the Joint European Societies guidelines on secondary cardiovascular prevention are followed in everyday practice. Design A cross-sectional ESC-EORP survey (EUROASPIRE V) at 131 centres in 81 regions in 27 countries. Methods Patients (<80 years old) with verified coronary artery events or interventions were interviewed and examined ≥6 months later. Results A total of 8261 patients (females 26%) were interviewed. Nineteen per cent smoked and 55% of them were persistent smokers, 38% were obese (body mass index ≥30 kg/m2), 59% were centrally obese (waist circumference: men ≥102 cm; women ≥88 cm) while 66% were physically active <30 min 5…

cardiovascular risk factorsMaleCardiac & Cardiovascular SystemsHeart diseaseEpidemiologymedicine.medical_treatmentHealth StatusEUROASPIRE ; cardiovascular risk factors ; guidelines ; lifestyle ; secondary preventionRisk Reduction Behavior*HSM CARRisk FactorsSecondary PreventionARTERY-DISEASEMyocardial infarctionEUROASPIREguidelinesDiet / adverse effectsRegistriesCardiovascular Diseases / physiopathology1102 Cardiorespiratory Medicine and HaematologyHydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*Smoking / epidemiologySmokingHealthy Lifestyle*Middle AgedPREVALENCEEuropeCardiovascular Diseases / diagnosisTreatment OutcomeCardiovascular DiseasesCardiovascular Agents / therapeutic use*LDL Cholesterol LipoproteinsFemaleEurope / epidemiologyCardiology and Cardiovascular MedicineLife Sciences & Biomedicinesecondary preventionmedicine.medical_specialtylifestyleSmoking / adverse effectsCardiovascular risk factorsHEART-DISEASERisk AssessmentLOW-INCOME COUNTRIESLife Style*Cardiovascular Diseases / prevention & control*Cardiovascular preventionmedicineJournal ArticleHumansHealthy Lifestyleddc:610Risk factorLife StyleAgedCardiovascular Diseases / epidemiologyScience & TechnologyTask forcebusiness.industryCardiovascular AgentsSMOKING-CESSATIONProtective Factorsmedicine.diseaseDietEUROASPIRE Investigators*Cross-Sectional StudiesMYOCARDIAL-INFARCTIONCLINICAL-PRACTICEFamily medicineHealth Care SurveysCardiovascular System & CardiologySmoking cessationPatient ComplianceHydroxymethylglutaryl-CoA Reductase InhibitorsSedentary BehaviorbusinessRisk Reduction BehaviorTASK-FORCE
researchProduct

Cost-effectiveness of optimized adherence to prevention guidelines in European patients with coronary heart disease : results from the EUROASPIRE IV …

2018

Background: This study aims to assess the cost-effectiveness of optimized guideline adherence in patients with a history of coronary heart disease. Methods: An individual-based decision tree model was developed using the SMART risk score tool which estimates the 10-year risk for recurrent vascular events in patients with manifest cardiovascular disease (CVD). Analyses were based on the EUROASPIRE IV survey. Outcomes were expressed as an incremental cost-effectiveness ratio (ICER). Results: Data from 4663 patients from 13 European countries were included in the analyses. The mean estimated 10-year risk for a recurrent vascular event decreased from 20.13% to 18.61% after optimized guideline a…

MaleCardiac & Cardiovascular SystemsCost effectivenessmedicine.medical_treatmentCost-Benefit AnalysisCoronary DiseaseDisease030204 cardiovascular system & hematology0302 clinical medicineOlder patientsMedicine030212 general & internal medicineguidelinesEUROASPIRE1102 Cardiorespiratory Medicine and Haematologyhealth care economics and organizationsBIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina.Framingham Risk ScoreSecondary preventionASSOCIATIONMiddle AgedhumanitiesCoronary heart diseaseEuropeDENSITY-LIPOPROTEIN CHOLESTEROLPractice Guidelines as TopicTRIALFemaleGuideline AdherenceCardiology and Cardiovascular MedicineLife Sciences & Biomedicinesecondary prevention ; guidelines ; cost-effectiveness ; coronary heart disease ; EUROASPIREsecondary preventionmedicine.drugINTERVENTIONSmedicine.medical_specialtyEZETIMIBEGuidelinesEVENTS03 medical and health sciencesEzetimibeInternal medicineHumansIn patientcoronary heart diseaseBIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine.cost-effectivenessMETAANALYSISAgedScience & Technologybusiness.industryDecision TreesSMOKING-CESSATIONCoronary heart diseaseTHRESHOLDSCardiovascular System & HematologyCardiovascular System & CardiologySmoking cessationCost-effectivenessbusinessSTATIN TREATMENT
researchProduct